Novo Nordisk's Growth Math Gets Harder as the Market Waits for Proof
Published on 09/24/2026 at 07:01 | Editorial boerse-global.de
Novo Nordisk shares closed Wednesday at EUR 33.66, down 2.2% on the day, as investors continued to digest a capital markets day that promised plenty for the next decade but offered little for the next few quarters. The Danish drugmaker's stock has now shed 24% since the start of the year, a decline that accelerated sharply right after management laid out its long-range targets, when the shares fell 8% in a single session.
At the heart of the selloff is a single uncomfortable question: can Novo Nordisk replace the revenue it will lose when Semaglutide's US patent expires in 2032? Management used the capital markets day to sketch an answer, pledging to bring more than five potential blockbuster medicines to market by 2030 and targeting risk-adjusted pipeline revenue of over DKK 150 billion by 2035. Chief executive Mike Doustdar framed the plan as a necessary pivot away from the company's reliance on a single product.
The problem is timing. Novo Nordisk told investors that revenue growth between 2026 and 2030 will slow to roughly the average pace of large pharmaceutical peers, drawing a line under the double-digit expansion of recent years. With no near-term catalysts to offset that guidance, the premium valuation the company has long commanded is now up for debate.
Clinical Data Offer a Counterweight
Optimists point to a pipeline that is still delivering. In the REIMAGINE-5 trial, CagriSema at a 1.0 mg / 1.0 mg dose produced a 12.4% weight reduction in adults with type 2 diabetes after 60 weeks. Eli Lilly's Tirzepatide, at its 5 mg dose, achieved 9.1% over the same period, while CagriSema also matched it on HbA1c reduction — a non-inferior result that keeps the candidate competitive.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A separate study found CagriSema drove 21.0% weight loss in overweight or obese adults, against just 2.0% for placebo. The company is also exploring alternative delivery methods to widen its addressable market.
Elsewhere in the portfolio, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval on September 18 for once-weekly Sogroya in idiopathic short stature in children. The file now sits with the European Commission, whose final decision is expected during 2026. A brand refresh on September 14, shortening the company's name to Novo, rounds out an effort to reposition the business both internally and externally.
Analysts Trim Their Targets
Sell-side sentiment has cooled in step with the shares. Deutsche Bank cut its price target to DKK 245 from DKK 265 and kept a sell rating. Jefferies, according to media reports, lowered its target to DKK 275 from DKK 285 while maintaining a hold recommendation.
The caution reflects concern that Novo Nordisk could lose ground in its core diabetes and obesity markets. Rivals led by Eli Lilly are pressing with competing offerings, and the looming loss of Semaglutide exclusivity threatens both margins and pricing power. If generic competition arrives faster than the new candidates generate revenue, current profitability levels could come under strain.
Levels to Watch
Technically, the stock's 52-week low of EUR 30.25 has become the line in the sand. Holding above it would suggest the market is willing to credit progress on CagriSema and the longer-term pipeline build-out. A sustained break below, however, would risk extending the correction as investors price in a deeper hit to future earnings.
The next real catalyst is likely to come from regulatory filings for CagriSema. Until then, shareholders face a straightforward calculation: weigh the pipeline's clinical wins against the transition risks that stretch to the end of the decade.
Ad
Novo Nordisk Stock: New Analysis - 24 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
